AGA111

DRUG2 trials

Sponsors

Angitia Biopharmaceuticals

Conditions

Degenerative Disc Disease

Phase 1

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

CompletedNCT05574543

Angitia BiopharmaceuticalsDegenerative Disc Disease

Start: 2020-12-01End: 2022-07-13Updated: 2022-10-10

Phase 3

A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

TerminatedNCT06115512

Angitia BiopharmaceuticalsDegenerative Disc Disease

Start: 2023-12-08End: 2026-06-12Updated: 2026-06-29